{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:33:21Z","timestamp":1767648801588,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02524-y","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T06:02:40Z","timestamp":1685512960000},"page":"3263-3278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EVELUT\u00ae: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA\/ICS to LAMA\/LABA or LAMA\/LABA\/ICS"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03954132","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roland","family":"Buhl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Mattiucci-Guehlke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Emerson-Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2524_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/COPD.S42866","volume":"8","author":"JL Lopez-Campos","year":"2013","unstructured":"Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231\u20138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2524_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: 2023 report. 2022. https:\/\/goldcopd.org\/wp-content\/uploads\/2022\/11\/GOLD-2023-ver-1.0-14Nov2022_WMV.pdf. Accessed 17 Nov 2022."},{"issue":"160","key":"2524_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2021","volume":"30","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Auladell-Rispau A, Monteagudo M, Vazquez-Niebla JC, Mohammed J, Nunez A, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160): 210075.","journal-title":"Eur Respir Rev"},{"key":"2524_CR4","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: 2022 report. 2021. Available from: https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/12\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed 12 Oct 2022."},{"key":"2524_CR5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.2147\/COPD.S262746","volume":"15","author":"R Buhl","year":"2020","unstructured":"Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, et al. A non-interventional study of tiotropium\/olodaterol versus any triple combination therapy for chronic obstructive pulmonary disease: The EVELUT\u00ae study protocol. Int J Chron Obstruct Pulmon Dis. 2020;15:2601\u20138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"2524_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12931-017-0682-y","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Cosio BG, Arnedillo A, Calle M, Alcazar-Navarrete B, Gonzalez C, et al. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res. 2017;18(1):198.","journal-title":"Respir Res"},{"issue":"1","key":"2524_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-022-02037-2","volume":"23","author":"CF Vogelmeier","year":"2022","unstructured":"Vogelmeier CF, Worth H, Buhl R, Criee CP, Guckel E, Kardos P. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD \u201creal world\u201d study. Respir Res. 2022;23(1):109.","journal-title":"Respir Res"},{"issue":"6","key":"2524_CR8","doi-asserted-by":"publisher","first-page":"2000351","DOI":"10.1183\/13993003.00351-2020","volume":"55","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Laska IF, Franssen FME, Janssens W, Pavord I, Rigau D, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351.","journal-title":"Eur Respir J"},{"key":"2524_CR9","doi-asserted-by":"crossref","unstructured":"Rothnie K, Gelwicks S, Numbere B, Lu Y, Sharma R, Compton C, et al. Identifying risk of first COPD exacerbation in COPD patients in GOLD group A\/B in the UK. European Respiratory Society International Congress; 2022 4\u20136 September; Barcelona, Spain, 2023, p. PA2110.","DOI":"10.1183\/13993003.congress-2022.647"},{"issue":"1","key":"2524_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-023-02311-x","volume":"24","author":"H Worth","year":"2023","unstructured":"Worth H, Buhl R, Cri\u00e9e C-P, Kardos P, G\u00fcckel E, Vogelmeier CF. In \u2018real world\u2019patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations. Respir Res. 2023;24(1):1\u20137.","journal-title":"Respir Res"},{"issue":"1","key":"2524_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","volume":"21","author":"D Singh","year":"2020","unstructured":"Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020;21(1):240.","journal-title":"Respir Res"},{"key":"2524_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2147\/COPD.S195852","volume":"14","author":"KO Steinmetz","year":"2019","unstructured":"Steinmetz KO, Abenhardt B, Pabst S, Hansel M, Kondla A, Bayer V, et al. Assessment of physical functioning and handling of tiotropium\/olodaterol Respimat\u00ae in patients with COPD in a real-world clinical setting. Int J Chron Obstruct Pulmon Dis. 2019;14:1441\u201353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"2524_CR13","doi-asserted-by":"publisher","first-page":"00004","DOI":"10.1183\/23120541.00004-2021","volume":"7","author":"A Gillissen","year":"2021","unstructured":"Gillissen A, Marseille A, Skowasch D, Ritz J, Mattiucci-Guehlke M, Pabst S, et al. Health and functional status of tiotropium\/olodaterol-treated patients with COPD: results from the AERIAL\u00ae non-interventional study. ERJ Open Res. 2021;7(3):00004\u20132021.","journal-title":"ERJ Open Res"},{"key":"2524_CR14","first-page":"891","volume":"11","author":"R Sauer","year":"2016","unstructured":"Sauer R, Hansel M, Buhl R, Rubin RA, Frey M, Glaab T. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis. 2016;11:891\u20138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"2524_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s41030-020-00127-4","volume":"6","author":"C Taube","year":"2020","unstructured":"Taube C, Bayer V, Zehendner CM, Valipour A. Assessment of patient experiences with Respimat\u00ae in everyday clinical practice. Pulm Ther. 2020;6(2):371\u201380.","journal-title":"Pulm Ther"},{"key":"2524_CR16","doi-asserted-by":"publisher","first-page":"147997312098622","DOI":"10.1177\/1479973120986228","volume":"18","author":"M Dreher","year":"2021","unstructured":"Dreher M, Price D, Gardev A, Peeters P, Arora S, van der Sar-Brugge S, et al. Patient perceptions of the re-usable Respimat\u00ae Soft Mist\u2122 inhaler in current users and those switching to the device: a real-world, non-interventional COPD study. Chron Respir Dis. 2021;18:1479973120986228.","journal-title":"Chron Respir Dis"},{"key":"2524_CR17","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.2147\/COPD.S169060","volume":"13","author":"J van der Palen","year":"2018","unstructured":"van der Palen J, Moeskops-van Beurden W, Dawson CM, James WY, Preece A, Midwinter D, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2515\u201323.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2524_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/COPD.S234823","volume":"15","author":"S Zhang","year":"2020","unstructured":"Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417\u201338.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2524_CR19","unstructured":"Boehringer Ingelheim Limited. Spiolto Respimat 2.5 microgram\/2.5 microgram, inhalation solution \u2013 Summary of Product Characteristics. 2023. https:\/\/www.medicines.org.uk\/emc\/medicine\/30495. Accessed 30 Jan 2023."},{"key":"2524_CR20","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.2147\/COPD.S204388","volume":"14","author":"A Valipour","year":"2019","unstructured":"Valipour A, Tamm M, Kocianova J, Bayer V, Sanzharovskaya M, Medvedchikov A, et al. Improvement In self-reported physical functioning with tiotropium\/olodaterol in Central and Eastern European COPD patients. Int J Chron Obstruct Pulmon Dis. 2019;14:2343\u201354.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2524_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"10","key":"2524_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, Gronke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"issue":"5","key":"2524_CR23","doi-asserted-by":"publisher","first-page":"1601446","DOI":"10.1183\/13993003.01446-2016","volume":"49","author":"V Koblizek","year":"2017","unstructured":"Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49(5):1601446.","journal-title":"Eur Respir J"},{"key":"2524_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2017.02.007","volume":"124","author":"P Kardos","year":"2017","unstructured":"Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi NS, Mailander C, et al. A two-year evaluation of the \u201creal life\u201d impact of COPD on patients in Germany: the DACCORD observational study. Respir Med. 2017;124:57\u201364.","journal-title":"Respir Med"},{"key":"2524_CR25","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/COPD.S308911","volume":"16","author":"W-C Huang","year":"2021","unstructured":"Huang W-C, Chen C-Y, Liao W-C, Wu B-R, Chen W-C, Tu C-Y, et al. A real world study to assess the effectiveness of switching to once daily closed triple therapy from mono\/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1555\u201368.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2524_CR26","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2147\/COPD.S115886","volume":"12","author":"AM Ciciliani","year":"2017","unstructured":"Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat\u00ae inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565\u201377.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"2524_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/15412555.2020.1853091","volume":"18","author":"AM Ciciliani","year":"2021","unstructured":"Ciciliani AM, Denny M, Langguth P, Voshaar T, Wachtel H. Lung deposition using the Respimat\u00ae Soft Mist inhaler mono and fixed-dose combination therapies: an in vitro\/in silico analysis. COPD. 2021;18(1):91\u2013100.","journal-title":"COPD"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02524-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:18:33Z","timestamp":1686806313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02524-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02524-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}